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Abstract
Background: Although it is well-known that early detection of colorectal cancer (CRC) is important for optimal
patient survival, the relationship of patient and health system factors with delayed diagnosis are unclear. The
purpose of this study was to identify the demographic, clinical and healthcare factors related to mode of CRC
detection and length of the diagnostic interval.
Methods: All residents of Alberta, Canada diagnosed with first-ever incident CRC in years 2004–2010 were identified
from the Alberta Cancer Registry. Population-based administrative health datasets, including hospital discharge abstract,
ambulatory care classification system and physician billing data, were used to identify healthcare services related to CRC
diagnosis. The time to diagnosis was defined as the time from the first CRC-related healthcare visit to the date of CRC
diagnosis. Mode of CRC detection was classified into three groups: urgent, screen-detected and symptomatic. Quantile
regression was performed to assess factors associated with time to diagnosis.
Results: 9626 patients were included in the study; 25% of patients presented as urgent, 32% were screen-detected and
43% were symptomatic. The median time to diagnosis for urgent, screen-detected and symptomatic patients were 6 days
(interquartile range (IQR) 2–14 days), 74 days (IQR 36–183 days), 84 days (IQR 39–223 days), respectively. Time to diagnosis
was greater than 6 months for 27% of non-urgent patients. Healthcare factors had the largest impact on time
to diagnosis: 3 or more visits to a GP increased the median by 140 days whereas 2 or more visits to a GI-specialist
increased it by 108 days compared to 0–1 visits to a GP or GI-specialist, respectively.
Conclusion: A large proportion of CRC patients required urgent work-up or had to wait more than 6 months for diagnosis.
Actions are needed to reduce the frequency of urgent presentation as well as improve the timeliness of diagnosis. Findings
suggest a need to improve coordination of care across multiple providers.
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Background
Colorectal cancer (CRC) is the second most common
cancer in men and the third most common cancer in
women in Canada. Every year almost 24,000 Canadians
are diagnosed with and 9,200 die from CRC [1]. The
diagnosis of CRC is often not straightforward. Symptoms
are often non-specific and commonly occur in benign
conditions [2]. Presentation and diagnosis are therefore
often delayed until the cancer is advanced [3]. Screening
asymptomatic individuals can effectively detect CRC
earlier; however, many nations, including Canada, have
either a relatively new or no colorectal screening pro-
gram [4, 5]. Early diagnosis of CRC is important because
5-year survival is much higher (90%) than that from
metastatic disease (11%) [6].
A long time from symptom onset to diagnosis or treat-
ment has been shown to contribute to cancer progres-
sion, higher stage disease and worse survival for cancer
patients [7–10]. Individuals diagnosed promptly may
benefit from timely treatment, which would improve
prognosis and decrease patient anxiety [11].
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Although there is consensus that patients should be
diagnosed in a timely manner, there is little information
regarding a reasonable length of diagnostic interval, that
is, time from patient first presentation to the healthcare
system to definitive diagnosis, or understanding of what
factors affect the length of the diagnostic interval.
Whether patients are diagnosed via screening or symp-
tomatic presentation, a typical pre-diagnostic work-up
may include visits to a family physician/general practi-
tioner (GP), diagnostic imaging tests, follow-up visits
and endoscopy, requiring a healthcare contacts with a
variety of care providers.
The patients who present with advanced stage cancer
are likely to be sicker, receive urgent care and be diag-
nosed more quickly than those who initially present with
early stage cancer [10]. Some in this latter group may
experience a prolonged diagnostic process because their
symptoms are not severe or specific, or they have a
chronic gastrointestinal (GI) condition that complicates
diagnosing the cancer. Others that are asymptomatic
may be diagnosed through screening. Screening may be
conducted through a formal program or via opportunis-
tic screening, as part of a visit for other reasons, notably
for preventive care. Furthermore, the diagnostic work-up
for CRC differs from most other common cancers be-
cause most CRCs are diagnosed by lower gastrointestinal
endoscopy [12]. Given the complexity of the relationship
between the patient’s clinical condition at first presenta-
tion, health system factors and the diagnostic interval,
investigation is warranted to better understand the rela-
tionship between these factors.
The purpose of the present study was to: 1) estimate
the proportion of CRC patients that are detected via an
opportunistic screening visit, urgent and non-urgent
symptom visits; 2) identify patient demographic, clinical
and healthcare utilization factors related to mode of
CRC detection; and 3) identify patient demographic,
clinical and healthcare utilization factors related to time
to diagnosis for non-urgent cases.
Methods
Study population
All residents of Alberta, Canada diagnosed in years 2004
to 2010 with malignant, invasive CRC (International
Classification of Disease for Oncology (ICD-O) 3rd edi-
tion codes C18-C20) were identified from the Alberta
Cancer Registry. Individuals with a first-ever primary
colorectal cancer were included. Patients were excluded
for the following reasons: 1) stage 0 cancer; 2) histology
that is not of colon origin (e.g., sarcomas, melanomas,
lymphomas); 3) unknown stage; 4) disease was not patho-
logically or microscopically confirmed; 5) prior history of
CRC or stomach cancer; 6) diagnosis of another cancer
within 6 months prior to diagnosis of CRC; and 7) missing
data that prevented identification of first visit prompting
diagnostic work-up.
Data sources and relevant healthcare encounters
Additional information obtained from the cancer regis-
try included age and residence at diagnosis, anatomic
site, and stage and date of diagnosis of tumor. The qual-
ity and completeness of the Alberta Cancer Registry has
consistently been shown to be very high [13].
Health service utilization prior to and related to CRC
diagnosis was obtained from three provincial administra-
tive health databases: 1) the Discharge Abstract Database
that contains inpatient data from all Alberta hospitals; 2)
the Ambulatory Care Classification System Database
that contains outpatient data from all Alberta hospitals;
and 3) the Physician Billing Database that contains
billing claims submitted by all physicians in Alberta
remunerated on a fee-for-service basis. These three
population-based datasets are routinely used in Canada
to conduct health services research. Validation studies
have shown them to have excellent sensitivity and speci-
ficity for identifying colorectal-related procedures and
have high face validity for diagnosis codes [14–16].
Health services related to CRC diagnosis were defined
using both procedure and diagnosis codes. Visits with
procedure codes of: 1) diagnostic imaging to the abdom-
inal or GI region including computerized tomography,
ultrasound, X-ray or barium enema, or 2) lower endos-
copy including colonoscopy and sigmoidoscopy were de-
fined as related to CRC diagnosis. Physician visits with
an ICD-9 or ICD-10 diagnosis code for any of: rectal
bleeding, anaemia, abdominal pain, obstruction, abscess/
fistula, constipation, perforation, diarrhea, weight loss,
or change in bowel habit were defined as CRC-related
[17–19]. Visits with any of the above diagnostic codes
were defined as visits with CRC-relevant symptoms.
‘Symptom visits’ that occurred in the absence of a CRC-
related procedure were further classified by type of
physician as follows: 1) ‘GI specialist’ included gastro-
enterology, internal medicine and general surgery; 2)
‘non-GI specialist’ included all other specialists; 3) ‘GP’
included general practitioners, primary care and family
physicians; and 4) ‘unknown provider-type’ when pro-
vider code was missing.
Diagnosis codes were also used to calculate Charlson
co-morbidity scores using ICD-9/10 codes in the year
prior to colorectal cancer diagnosis as described by Deyo
et al. and updated for ICD-10 codes developed by Quan
et al. [20, 21]. The Charlson comorbidity index was ori-
ginally developed to estimate death within one year of
hospitalization. The Charlson-Deyo index considers 17
comorbid conditions each with an associated weight,
ranging from 1 to 6, based on the adjusted risk of mor-
tality. The sum of all the weights results in a single
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comorbidity score for a patient. The Charlson score for
each patient was categorized into three groups: 0, 1 and
≥2 to indicate no, mild and moderate-to-severe comor-
bidities. Chronic gastrointestinal (GI) tract conditions
were also identified using ICD-9/10 codes in the year
prior to diagnosis including: irritable bowel syndrome,
irritable colon, Crohn's disease, ulcerative colitis, enter-
itis and diverticular disease of intestine, ulcer of anus
and rectum and chronic vascular insufficiency intestine.
These conditions are distinct from the Charlson co-
morbidities as they were selected based on discussion
with the authors and additional primary care physicians
regarding conditions that may complicate the diagnosis
of CRC, as opposed to predicting mortality. Each patient
was identified with presence or absence of GI-related co-
morbidities. The Usual Provider Continuity (UPC) index,
a measure of continuity of care with a primary care
physician, was derived based on GP visits in the two
years prior to diagnosis [22]. Statistics Canada data from
2006 were used as a source of patients’ median house-
hold income for each census dissemination area (DA),
an area including approximately 600 households.
Definition of diagnostic interval
The diagnostic interval was defined as the time from the
first CRC-related healthcare visit to the date of CRC
diagnosis, as suggested by the Refined Anderson Model
of Total Patient Delay within the constraints of the
administrative data used for the study [23]. The first
CRC-related healthcare visit was defined as the earliest
of three record dates: 1) the most proximal GP visit
prior to the first diagnostic imaging test, 2) the most
proximal GP visit prior to the first endoscopy, or 3) the
first date of GI symptoms (Fig. 1a). For (1) and (2), the
date of the most proximal GP visit prior to the respect-
ive procedure was assumed to be the date the patient re-
ceived a referral for the procedure. This assumption was
made because in Alberta patients very seldom receive a
specialist procedure or see a specialist without a referral.
The referral usually comes from a GP. The exception to
this is if a patient presents in an urgent state to an emer-
gency department (ED). For this reason, if the first diag-
nostic imaging or endoscopy was performed in an ED
and the patient did not have any prior record of a
healthcare visit with GI symptoms then the ED visit
was assumed to be the first healthcare contact. A one-
year look-back period from the date of CRC diagnosis
was used to identify relevant diagnostic imaging tests
and endoscopies based on a sensitivity analysis we con-
ducted that found roughly the same number of tests 12,
18, or 24 months prior to colorectal cancer diagnosis.
A 6-month look-back period from date of diagnostic
imaging or endoscopy was used to identify the GP re-
ferral visit – based on the recommendation by the
Canadian Association of Gastroenterology [24] for the
target maximal wait time from referral to procedure
completion in absence of a symptom. To be consistent
with the maximum timeframe for GP visits prior to
Fig. 1 Illustrative flowchart for a) definition of CRC diagnostic interval and b) mode of CRC detection. CRC =Colorectal cancer, GI = Gastrointestinal, GP =
General practitioner, ED= Emergency Department; ±GP visit refers to the most proximal GP visit prior to the first diagnostic imaging test or endoscopy exam
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diagnosis, an 18-month look-back period was used to
identify all records with GI-related symptoms.
Definition of mode of CRC detection
The study patients were classified by their mode of CRC
detection: urgent, screen-detected or symptomatic,
depicted in Fig. 1b. Presentation was defined as ‘urgent’
if the diagnostic interval was less than 30 days and the
patient had any of the following: 1) an ED visit within
the diagnostic interval; 2) a GI specialist visit within
2 days after the GP visit; or 3) an endoscopy performed
within 3 days after the GP visit. The rationale for (2) and
(3) is based on recommendations from the Canadian
Association of Gastroenterology which state that emer-
gency cases should be seen and endoscopy performed
within 24 h following referrals [25]. To allow timing to
contact the specialist and preparation for endoscopy, we
extended this to 2 and 3 days, respectively. Patients were
classified as screen-detected if their first CRC-related
healthcare visit was a periodic preventive care visit with
a GP, identified by the corresponding procedure code in
the Physician Claims data, and they had not been classi-
fied as “urgent”. At that time, Alberta did not have a for-
mal colorectal cancer screening program, thus the only
screening that occurred was opportunistic, typically initi-
ated at periodic preventive care visits. Many Canadians
have a preventive care visit, typically once every year, to
their family physicians, which is paid by the govern-
ment’s universal healthcare system. Unlike usual primary
care, a periodic preventive care visit allows individuals to
undertake screening tests recommended based on the
patient age, sex, family history, etc. The remaining
patients were categorized as “unscreened”, and are, by
exclusion, non-urgent and likely symptomatic.
Statistical analysis
The primary outcomes were mode of CRC detection and
time to diagnosis. Descriptive statistics were calculated
to describe the association of patient demographics,
clinical characteristics and healthcare utilization by
mode of CRC detection: urgent; screening; or symptom-
atic. Healthcare utilization factors were categorized
based on the frequency distribution of each variable.
Chi-square test for categorical variables and Jonckheere-
Terpstra trend test for ordinal variables were used to
assess statistical significance.
By definition, the length of the diagnostic interval for
urgently diagnosed patients is ≤30 days, therefore, this
patient group was excluded from the analyses examining
factors related to time to diagnosis. The median and 75th
percentile time to diagnosis in days was calculated for
each variable of interest. The Kruskal Wallis test was
used to assess for differences across medians within each
categorical variable. Multivariable quantile regression
was used to ascertain the association of demographic,
clinical and healthcare utilization factors to the diagnos-
tic interval (days). Quantile regression was used rather
than the more typically used ordinary least square re-
gression (OLS) model because the former allows exam-
ination of the way factor-effects change with increased
time to diagnosis. Unlike OLS, quantile regression
makes no distributional assumption about the error term
in the model, and it offers considerable model robust-
ness. Furthermore, the interpretation of the estimates is
the difference in days associated with each factor relative
to the reference group, making it simple to understand.
All factors evaluated in the unadjusted analysis were in-
cluded in the quantile regression except the number of
diagnostic imaging tests and unknown provider-type to
address issues of co-linearity. Backward elimination
method was used to identify the most parsimonious re-
gression model for the 50th and 75th percentiles.
All statistical analyses were performed using statistical
software SAS 9.3 (SAS Institute, Cary, NC, USA).
Results
A total of 11,241 patients were diagnosed in Alberta
with colorectal cancer from 2004 to 2010. There were
1,615 patients excluded from the study for the following
reasons: 477 had stage 0 cancer or a cancer histology
that was not a CRC solid tumor; 467 had unknown
stage; 229 did not have pathologic or microscopic con-
firmation of disease; 184 had a prior history of CRC or
stomach cancer; 134 were diagnosed with another can-
cer within 6 months prior to the diagnosis of CRC; and
124 had no record of healthcare visits within 1.5 year
prior to CRC diagnosis preventing estimation of time to
diagnosis. The study cohort included the remaining
9,626 patients.
Patients by mode of CRC detection and related factors
The median age of patients at diagnosis was 69 years
and 57% were male. Approximately 25% of patients
(2428) presented as urgent, 32% (3083) were screen-
detected and 43% (4115) were non-urgent symptomatic.
Table 1 shows the distribution of patient demographic
and clinical characteristics by mode of CRC detection.
Compared to screen-detected and symptomatic patients,
urgent patients were significantly more likely to be older
than 80 years, have colon rather than rectal cancer, stage
IV tumor and a Charlson comorbidity score of 2 or
higher but not have GI-related comorbidities. The
screen-detected patients were most likely to be between
60 and 79 years, not have comorbidities, and reside in
one of the two major cities, Calgary or Edmonton.
Table 2 shows the relationship between mode of CRC
detection and healthcare utilization. Screen-detected
patients were most likely to have medium to high
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continuity of usual provider care and patients who pre-
sented urgently were least likely, 79% versus 63%, re-
spectively. A small proportion of patients, 5–7%, had
one or more visits with a symptom to a non-GI
specialist, regardless of mode of CRC detection. Non-
urgent symptomatic patients had the highest number of
total physician visits prior to diagnosis, with 41% having
Table 1 Patient and clinical characteristics by mode of
colorectal cancer diagnosis (n = 9626)
Urgent Screen-detected Symptomatic p-valuea
(n = 2428) (n = 3083) (n = 4115)
n (%) n (%) n (%)
Patient characteristics
Age at diagnosis
< 50 228 (9) 211 (7) 383 (9) 0.0429
50–59 461 (19) 519 (17) 757 (18)
60–69 586 (19) 792 (26) 1015 (25)
70–79 599 (25) 1011 (33) 1230 (30)
≥ 80 554 (23) 550 (18) 730 (18)
Residential zonesb
Calgary 804 (33) 1084 (35) 1226 (30) <.0001
Central 334 (14) 357 (12) 741 (18)
Edmonton 836 (34) 1088 (35) 1320 (32)
North 274 (11) 292 (9) 463 (11)
South 180 (7) 262 (9) 364 (9)
Median annual household income
< $45389 647 (27) 705 (23) 993 (24) 0.4062
$45389 - $59119 590 (24) 681 (22) 1074 (26)
$59119 - $80148 595 (25) 789 (26) 964 (23)
≥ $80148 547 (23) 837 (27) 962 (23)
Missing 49 (2) 71 (2) 122 (3)
Clinical characteristics
Anatomic site
Colon 1672 (69) 1943 (63) 2471 (60) <.0001
Rectum 756 (31) 1140 (37) 1644 (40)
Stage at diagnosis
I 280 (12) 781 (25) 886 (22) <.0001
II 670 (28) 831 (27) 1150 (28)
III 701 (29) 879 (29) 1191 (29)
IV 777 (32) 592 (19) 888 (22)
Charlson comorbidity score
0 1359 (56) 1985 (64) 2528 (61) 0.0025
1 601 (25) 675 (22) 893 (22)
≥ 2 468 (19) 423 (14) 694 (17)
Gastrointestinal comorbidities
Yes 544 (22) 827 (27) 1062 (26) 0.0005
No 1884 (78) 2256 (73) 3053 (74)
aJonckheere-Terpstra trend test for ordinal variables (age, income, comorbidity
score and stage at diagnosis) and Chi-square test for the other categorical variables
were used to compare proportions. bOne patient with unknown residential zone
was excluded from this calculation
Table 2 Healthcare utilization by mode of colorectal cancer
diagnosis (n = 9626)
Healthcare Utilization Urgent Screen-detected Symptomatic p-valuea
(n = 2428) (n = 3083) (n = 4115)
n (%) n (%) n (%)
UPC index <.0001
<3 primary care visits 276 (11) 76 (2) 159 (4)
Low (<50%) 620 (26) 586 (19) 904 (22)
Medium (50%–80%) 821 (34) 1129 (37) 1440 (35)
High (>80%) 711 (29) 1292 (42) 1612 (39)
Physicians visits with GI-related symptom
Visits to any physician
0–1 1437 (59) 1063 (34) 1138 (28) <.0001
2 631 (26) 1008 (33) 1302 (32)
3 218 (9) 452 (15) 767 (19)
4 81 (3) 240 (8) 365 (9)
≥ 5 61 (3) 320 (10) 543 (13)
GP visits
0–1 2093 (86) 1859 (60) 2235 (54) <.0001
2 254 (10) 856 (28) 1230 (30)
3 44 (2) 200 (6) 333 (8)
≥ 4 37 (2) 168 (5) 317 (8)
GI specialist visits
0 1761 (73) 2106 (68) 2771 (67) <.0001
1 538 (22) 751 (24) 990 (24)
≥ 2 129 (5) 226 (7) 354 (9)
non-GI specialist visits
0 2266 (93) 2918 (95) 3868 (94) 0.4904
≥ 1 162 (7) 165 (5) 247 (6)
Unknown provider-type visits
0 1822 (75) 2411 (78) 2975 (72) <.0001
1 528 (22) 462 (15) 777 (19)
≥ 2 78 (3) 210 (7) 363 (9)
Visits for GI-related Procedure
Endoscopies
0 468 (19) 206 (7) 340 (8) <.0001
1 1657 (68) 2360 (77) 3051 (74)
≥ 2 303 (12) 517 (17) 724 (18)
Diagnostic imaging tests
0 1092 (45) 1551 (50) 1893 (46) 0.0001
1 1002 (41) 917 (30) 1270 (31)
2 247 (10) 381 (12) 589 (14)
≥ 3 87 (4) 233 (8) 362 (9)
Abbreviations: UPC Usual provider care, GP General practitioner, GI Gastrointestinal,
aJonckheere-Terpstra trend test was used to compare proportions
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three or more visits compared to 33% of screen-detected
and 15% of urgent patients; the increase was primarily
due to larger numbers of GP visits with 16, 11 and 4% of
non-urgent symptomatic, screened and urgent patients,
respectively, having 3 or more GP visits.
Time to diagnosis
Table 3 shows the median and 75th percentile time to
diagnosis for the non-urgent patients by the demo-
graphic, clinical and healthcare utilization factors exam-
ined. The overall median and 75th percentile time to
diagnosis was 79 and 206 days, respectively. The median
time for screen-detected patients was 74 days (interquar-
tile range (IQR) 36–183 days) compared to 84 days (IQR
39–223 days) for symptomatic patients. The oldest pa-
tients, those > 80 years, had the longest diagnostic inter-
val, with a median of 105 days, while patients aged
60–69 years had the shortest median at 69 days. The
clinical factor that had the largest relationship to the
length of the diagnostic interval was Charlson comorbid-
ity index: those with a score of 2 or more had a median
of 147 days compared to 70 days for those with a score
of 0. In general, healthcare utilization factors affected
the length of the diagnostic interval much more than
patient demographic or clinical factors. The median
diagnostic interval for patients with 5 or more CRC-
symptom-related visits was significantly longer than the
median for those with 0 or 1 CRC-symptom-related
visits, 287 days and 38 days, respectively. Similarly, the
median diagnostic interval for those with 3 or more
CRC-symptom-related visits to a GP was 224 days com-
pared to 56 for those with 0 or 1 visits and 224 days for
those with 2 or more CRC-symptom-related visits to a
GI specialist compared to a median of 102 days for those
with 1 visit to a GI-specialist.
Table 4 presents the results of the quantile regression
models at the 50th and 75th percentiles.
The results are qualitatively similar to the unadjusted
analysis shown in Table 3. The demographic and clinical
factors with the largest effect were age: median diagnos-
tic interval for oldest patients was 14 days longer than
those aged 60–69 years; stage: median diagnostic interval
for stage 1 patients was 26 days longer than stage IV pa-
tients; Charlson comorbidity score: median diagnostic
interval was 32 days longer for those with a score of 2 or
more compared to those with a score of 0.
The number of GP and GI specialist visits for CRC
symptoms had the largest impact on the length of the
diagnostic interval after adjusting for demographic, clin-
ical and other healthcare utilization factors. Compared
to patients with 0–1 GP visit with CRC symptoms, the
median diagnostic interval for those with 2 or ≥3 was 44
and 141 days longer, respectively. Similarly, compared to
patients who did not have any visits for CRC symptoms
to a GI specialist, those who had 1 or ≥2 visits had a me-
dian diagnostic interval that was 33 and 108 days longer,
respectively. Having any CRC-symptomatic visits to a
non-GI specialist, however, was associated with almost
3 months longer median time to diagnosis.
Discussion
In Alberta, Canada, a province with universal health
coverage but without a formal colorectal screening pro-
gram at the time of the study, 25% of patients presented
as urgent while 20% had a diagnostic interval over
6 months, representing 45% of all newly diagnosed CRC
patients over a 6-year period. Tørring et al. has shown
that CRC patients with very short or very long diagnos-
tic intervals have higher mortality [10]; efforts are clearly
needed to improve the CRC diagnostic care process.
Patients most likely to present as urgent were 80 years
or older, have colon cancer, stage IV disease, and have
multi-morbidities. The demographic and clinical factors
that had the greatest impact on the length of the diag-
nostic interval were age greater than 80 years, stage I
disease, and presence of multi-morbidities. Healthcare
utilization factors had a much larger effect on the length
of the diagnostic interval than clinical factors, however,
with each GP or GI specialist visits for symptoms adding
more than a month to the median time and a visit to a
non-GI specialist for symptoms adding almost 3 months
to the median time. Colon cancer is often difficult to
diagnose, with non-specific symptoms developing slowly,
whose import may be difficult for the patient to
recognize, or require investigation or initial referral to a
non-GI specialist. Therefore it is possible that many of
these patients presented with non-specific findings that
led to indirect routes of investigation and referral, before
the correct diagnosis was determined. Regardless, these
findings suggest that inefficiencies in the healthcare sys-
tem are the most critical remediable factors to address.
A total of 32% patients identified as screen-detected
via periodic preventive care check-up. Results from a
2009 survey showed that 43% of Albertan’s aged 50–74
years were up-to-date with their CRC screening [26].
This is reasonable given that our study included patients
with CRC of all ages, whereas the screening rate is low
in younger population. One possible improvement is to
introduce a formal CRC screening program to decrease
the percentage of patients presenting as urgent [27].
Regular screening addresses the difficulty of non-specific
presentations by identifying cancer before symptoms
begin. Countries with a national screening program,
such as Germany, Italy and Australia, have reported ur-
gent presentation rates ranging from 6 to 19% [28–30]
significantly less than 25% found in the current study.
Building awareness among patients and practitioners in
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understanding and recognizing the potential seriousness
of symptoms is equally important. Educational efforts in
combination with routine screening would help to
mitigate patient- and practitioner-related factors of late
presentation as well as clinical complexities due to non-
specific symptoms [31, 32].
The patient population at highest risk for urgent pres-
entation was those greater than 80 years with multi-
morbidities. Likewise, these patients were also at highest
risk for a long diagnostic interval. Other studies have
also found that older patients and those with comorbidi-
ties have long diagnostic intervals; this may be due to
missed opportunities related to non-specific symptoms,
signs, and abnormal tests [33]. Providers may also be
distracted from investigating GI symptoms or be hesi-
tant to refer older patients to colonoscopy because of
Table 3 Median and 75th percentile of time to diagnosis of
non-urgent colorectal cancer patients (n = 7198)
Factors Time to diagnosis (days)
Median 75th percentile p-valuea
Overall 79 206
Patient and clinical factors
Age at diagnosis




≥ 80 105 286
Residential zones





Median annual household income
< $45389 80.5 234 0.0035
$45389 - $59119 87 219
$59119 - $80148 77 196
≥ $80148 74 177
Missing 74 278
Anatomic site
Colon 87 227 <.0001
Rectum 70 171.5
Stage at diagnosis





0 70 164 <.0001
1 88 219
≥ 2 147 322
Gastrointestinal comorbidities




< 3 primary care visits 50 112 <.0001
Low (<50%) 90 231
Medium (50%–80%) 87 223
High (>80%) 73 181.5
Table 3 Median and 75th percentile of time to diagnosis of
non-urgent colorectal cancer patients (n = 7198) (Continued)
Visits to any physician




≥ 5 287 436
GP visits
0–1 56 127 <.0001
2 104 245
≥ 3 226 384
GI specialist visits
0 64 160 <.0001
1 102 245
≥ 2 224.5 413
non-GI specialist visits
0 76 194 <.0001
≥ 1 201 358
Endoscopies
0 97 271 <.0001
1 71 176
≥ 2 129 285
Diagnostic imaging tests
0 61 135 <.0001
1 84 226
2 125 290
≥ 3 183 302
Method of detection
Screen-detected 74 183 0.0002
Symptomatic 84 223
aKruskal-Wallis test was used to compare medians across the groups
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the higher complication rate in this population. Even
with a screening program, cases will still present among
the old, as will those not detected by screening. There-
fore, the health care system must still identify and man-
age such patients presenting with symptoms.
The median length of the diagnostic interval was 79 days
and the 75th percentile was 206 days for screen-detected
and symptomatic patients in our study. Two other
population-based studies conducted in Canada that in-
cluded slightly older patient cohorts, diagnosed in years
2001–2005, reported a median diagnostic interval of
44–64 days (depending on year of diagnosis) [12] and
44 days [34]. The two studies used similar methods to
ours, however, an important difference is that we excluded
urgent patients from the calculation of the diagnostic
interval whereas the other two did not. If we include ur-
gent patients, the median diagnostic interval was 55 days
in our study with 37% of all patients diagnosed within
4 weeks, similar to 37.1% found by Porter et al. [34]. A
multicenter US study that included mainly male patients
of Veteran Affairs hospitals reported a median diagnostic
interval of 91 days for screen-detected and 74 days for
symptom-detected CRC [33]. Another observational study
in Northern Holland reported a median diagnostic inter-
val of 23.5 weeks (i.e., 165 days) using prospectively col-
lected data [2]. The median diagnostic interval that the
present study reported is similar to Fisher et al. [33], but
much shorter compared to the other non-Canadian stud-
ies [2]. This difference may be partly due to differences in
patient populations and study design but could also reflect
differences in the healthcare systems.
Among the healthcare utilization factors, the increased
number of GI-related healthcare visits for pre-diagnostic
work-up had the greatest impact on the length of the
diagnostic interval. If the diagnostic interval comprises
discrete intervals, the primary care interval and the sec-
ondary care interval, as proposed by Olesen et al. [35],
this finding is particularly interesting given our methods
Table 4 Quantile regression estimates of the median and 75th
percentile of the diagnostic interval for non-urgent colorectal cancer
patients (n= 7198). The estimate associated with each category is
the difference in days when compared to the reference category
Q0.50 Q0.75
Days P-value Days P-value
Intercept 7.28 0.89 15 0.08
Age at diagnosis
< 50 2.33 0.5 −0.96 0.92
50–59 4.85 0.09 3.39 0.58
60–69 0 . 0 .
70–79 5 0.0425 8.59 0.17
≥ 80 14.27 0.0001 34.28 0.0003
Residential Zones
Calgary 0 . 0 .
Central 3.18 0.33 9.23 0.25
Edmonton −0.62 0.81 1.13 0.85
North 0.98 0.79 8.67 0.44
South −7.15 0.0189 −15.33 0.0455
Anatomic site
Colon 6.47 0.0014 9.56 0.0536
Rectum 0 .
Stage at diagnosis
I 25.67 <.0001 42.13 <.0001
II 8.47 0.0013 14.03 0.031
III 11 <.0001 23.98 0.0001
IV 0 . 0 .
Charlson Comorbidity Score
0 0 . 0 .
1 5.13 0.0371 19.21 0.0025
≥ 2 31.86 <.0001 82.24 <.0001
GI comorbidity
No 6.4 0.0014 29.18 <.0001
Yes 0 . 0 .
Usual Provider Continuity
< 3 primary care visits 4.52 0.35 13.54 0.39
Low < =50% 5.47 0.07 18.34 0.0046
Medium 5080% 4.87 0.06 11.64 0.0269
High >80% 0 . 0 .
# of GP visits
0–1 0 . 0 .
2 44.13 <.0001 91.45 <.0001
≥ 3 140.8 <.0001 201.59 <.0001
# of GI specialist visits
0 0 . 0 .
1 33.46 <.0001 50.68 <.0001
≥ 2 108.54 <.0001 153.56 <.0001
Table 4 Quantile regression estimates of the median and 75th
percentile of the diagnostic interval for non-urgent colorectal cancer
patients (n= 7198). The estimate associated with each category is
the difference in days when compared to the reference category
(Continued)
# of non-GI specialist visits
0 0 . 0 .
≥ 1 81.55 <.0001 101.56 <.0001
# of endoscopy
0 17.44 <.0001 52.66 <.0001
1 0 . 0 .
≥ 2 36.05 <.0001 50.43 <.0001
The unconditional percentiles corresponded to diagnostic interval cut-off
values are Q0.50 = 79 and Q0.75 = 206 days
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likely underestimate the length of the primary care inter-
val since our start date is likely the date of referral from
primary to secondary care. The fact that there were a
higher proportion of patients with multiple GP visits
than specialist visits suggests that the primary and sec-
ondary care intervals overlap in our study population
significantly more than the ideal diagnostic care trajec-
tory for a significant proportion of the population. While
multiple visits may adversely affect time to diagnosis and
the experience of care, our data do not enable us to
identify the reasons for multiple visits to physicians:
clinical complexity of the disease, misleading symptoms,
reasonable watchful waiting, delay in appropriate investi-
gations to confirm diagnosis, or possibly suboptimal pro-
fessional performance of healthcare providers. A recent
review suggests that diagnostic difficulty and the need
for investigation of poorly differentiated symptoms in
primary care are more likely to be the drivers for mul-
tiple visits than poor diagnostic reasoning and subopti-
mal professional practice [36]. Patient factors, including
cancer awareness, beliefs and attitudes before presenta-
tion to healthcare system, are also factors contributing
to delayed diagnosis [37]. On the contrary, others have
found that poor physical examination and misdiagnosis
by both primary and hospital physicians might contrib-
ute to repeated visits and lengthen time to diagnosis
[38]. Increased healthcare utilization may also be due to
1) GP’s perception of needing more follow-up visits prior
to referring for endoscopy, 2) management during the
wait for “non-urgent” specialist consultation and 3) lack
of service integration that would allow provision of mul-
tiple services at the same patient visit by the same
healthcare provider or clinical team [12, 39].
Strengths and limitations
Several limitations of the current study should be ac-
knowledged. First, there will be a proportion of mis-
classification of the CRC presentation groups: urgent,
screened, and symptomatic. We purposefully used a con-
servative definition for classifying urgent patients to
minimize the chance of overestimation, however, in the
absence of procedure codes indicating purpose of a test
(i.e., screening or diagnostic) there will be misclassifica-
tion in the screened and symptomatic groups, specific-
ally, it is likely symptomatic patients who were identified
at a preventive care visit are included in the ‘screened’
group. Second, it is not possible to determine whether
patients presented urgently because they ignored early
symptoms or because of errors and/or inefficiencies in
the healthcare system, Similarly, it is not possible from
this study to ascertain the extent of delays between
physician appointments and tests due to patient lack of
urgency, those due to system inefficiencies, or those due
to valid clinical difficulty in diagnosis. In identifying time
to diagnosis, we restricted the length of time to a max-
imum 18 months. This may result in underestimating
the length of time to diagnosis for certain individuals
given that a few patients may have presented to GP prior
to the first contact we identified but is unlikely to have
affected the median or 75th percentile, both of which
were considerably less than 18 months.
A major strength of the study is that it is population-
based and included all histologically confirmed incident
colorectal cancer cases over a 7-year period, minimizing
the potential for selection bias. Quantile regression
allowed us to estimate the effect factors of interest had
directly on the length of the diagnostic interval, with re-
spect to the median and 75th percentile. We also used
an innovative definition of urgent presentation by com-
bining multiple events of urgent nature (i.e., time to
diagnosis, time and status of ED visit, endoscopy exams
and specialist visit).
Implications and areas for further research
The relationship between timeliness of care and factors
associated with the pre-diagnostic healthcare delivery is
complex. Actions are needed to reduce the frequency of
urgent presentation as well as improve the timeliness of
diagnosis. Both of these can be addressed to some extent
by implementation of an organized screening program
in the eligible general population, however, many cases
will continue to present despite the program, and sys-
tems must assist these patients too. The effect on re-
source utilization is critical when developing and
implementing an organized screening program, which
may increase number of diagnoses [40, 41]. The goal of
reducing time to diagnosis can also be achieved by better
service integration and coordination of care across ser-
vice providers [39].
Conclusion
Major efforts are needed to 1) identify CRC at an early
stage when it is treatable, for instance, through an orga-
nized screening program and 2) to develop, test, and im-
plement care models that address the healthcare needs
of those with multiple morbidities in a timely fashion. A
province-wide colorectal screening program has been re-
cently instituted; the current study provides strong base-
line data that can be used to evaluate the screening
program’s effectiveness in decreasing the frequency of
urgent presentation and improving timely diagnosis.
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